Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
57.50
+0.12 (+0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Legend Biotech Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
42 Stocks Moving In Tuesday's Mid-Day Session
May 18, 2021
Gainers Agenus Inc. (NASDAQ: AGEN) shares surged 33.4% to $4.35. Bristol-Myers Squibb Co and Agenus entered into a global exclusive license agreement, under which Bristol Myers...
Via
Benzinga
Legend Biotech Reports First Quarter 2021 Financial Results and Recent Highlights
May 18, 2021
From
Legend Biotech Corporation
Via
Business Wire
Week In Review: GenScript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse
May 15, 2021
GenScript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to GenScript's Legend Biotech CAR-T subsidiary. Before the...
Via
Talk Markets
28 Stocks Moving in Friday's Pre-Market Session
May 14, 2021
Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares rose 28.5% to $0.7451 in pre-market trading after the company reported better-than-expected Q1 sales. Bionano Genomics, Inc. (NASDAQ:...
Via
Benzinga
Legend Biotech Reports New and Updated Data from BCMA CAR-T Program at 2021 ASCO and EHA Meetings
May 12, 2021
From
Legend Biotech
Via
Business Wire
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
May 01, 2021
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million...
Via
Talk Markets
Legend Biotech Announces Submission of European Marketing Authorisation Application for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
April 30, 2021
From
Legend Biotech Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.